Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma

Table 1 Clinical outcomes from studies comparing drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization in patients with intermediate-stage hepatocellular carcinoma

Ref.	Study design	Arm	BCLC stage n (A/B/C)	Clinical outcomes in intermediate-stage (BCLC-B) (DEB-TACE/cTACE)
				OS rate	P value	TTP	P value	Response rate	P value
Lammer et al[10]	RCT	DEB-TACE	24/69/0	NR		NR		OR 52.4%/34.7%2	0.038
		cTACE	29/79/0					DC 63.5%/44.4%2	0.026
Wiggermann et al[46]1	Retrospective	DEB-TACE	1/17/3	70%/55% (1-yr survival rate)	0.01	NR		OR 22.7%/22.7%3
		cTACE	4/15/2					DC 90.9%/68.2%3	0.066
Song et al[9]	Retrospective	DEB-TACE	27/33/0	DEB > cTACE (log-rank test)	0.020	DEB > cTACE (log-rank test)	0.038	OR 75.6%/34.1%4	< 0.001
		cTACE	28/41/0
Golfieri et al[35]	RCT	DEB-TACE	41/26/22	NR		NR		CR 19.2%/26.1%5	0.734
		cTACE	41/23/24					CR 42.1%/22.2%6	0.295

¹In this study, subgroup analysis according to BCLC stage was not performed. However, majority of patients was BCLC-B (DEB-TACE, 81%; cTACE, 71%);

²The 6-mo tumor response rate, according to the European Association for the Study of the Liver response criteria;

³The average 8-mo tumor response rate, according to the EASL response criteria;

⁴The 3-mo tumor response rate, according to the mRECIST;

⁵The 1-mo;

⁶The 6-mo tumor response rate, according to the EASL criteria and mRECIST. RCT: Randomized controlled trial; OS: Overall survival; TTP: Time to progression; NR: Not reported; OR: Objective response; DC: Disease control; CR: Complete response; mRECIST: Modified Response Evaluation Criteria in Solid Tumors; BCLC: Barcelona Clinic Liver Cancer; TACE: Transarterial chemoembolization; DEB: Drug-eluting bead.